Considering the high PD-L1 expression within TME, the bifunctional anti-PD-L1/TGF-βRII fusion protein BR102 could be anticipated to lead to a more tumor-targeted inhibition of TGF-β within the TME and reduce safety concerns associated with some TGF-β targeted therapies. The gene discussed is CD274; the disease is neoplasm.